Megan A. Griffey, Ph.D.
Affiliations: | 2004 | Washington University, Saint Louis, St. Louis, MO |
Area:
Molecular geneticsGoogle:
"Megan Griffey"Mean distance: 21373.2 (cluster 6)
Parents
Sign in to add mentor| Mark S. Sands | grad student | 2004 | Washington University | |
| (Infantile neuronal ceroid lipofuscinosis: Characterization of a murine model and viral -mediated gene therapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Galvin N, Vogler C, Levy B, et al. (2008) A murine model of infantile neuronal ceroid lipofuscinosis-ultrastructural evaluation of storage in the central nervous system and viscera. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 11: 185-92 |
| Kielar C, Maddox L, Bible E, et al. (2007) Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiology of Disease. 25: 150-62 |
| Griffey MA, Wozniak D, Wong M, et al. (2006) CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 538-47 |
| Griffey M, Macauley SL, Ogilvie JM, et al. (2005) AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 413-21 |
| Griffey M, Bible E, Vogler C, et al. (2004) Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiology of Disease. 16: 360-9 |
| Griffey M, Wozniak D, Wong M, et al. (2004) AAV-mediated gene therapy causes functional improvements in a murine model of infantile neuronal ceroid lipofuscinosis (INCL, Batten disease) Molecular Therapy. 9 |